These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9408020)

  • 1. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients.
    Freyburger G; Javorschi S; Labrouche S; Bernard P
    Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
    Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
    Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
    Svensson PJ; Zöller B; Dahlbäck B
    Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R; Quehenberger P; Wu JR; Wilmer M
    Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
    Tripodi A; Negri B; Bertina RM; Mannucci PM
    Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA; Fox EA; Longtine JA; Dorfman DM
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical and biological conditions influencing the functional APC resistance test.
    Freyburger G; Bilhou-Nabera C; Dief S; Javorschi S; Labrouche S; Lerebeller MJ; Boisseau MR
    Thromb Haemost; 1996 Mar; 75(3):460-5. PubMed ID: 8701408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C; Dahlbäck B
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma.
    Tripodi A; Chantarangkul V; Negri B; Mannucci PM
    Thromb Haemost; 1998 Mar; 79(3):564-6. PubMed ID: 9531041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
    Rosén S; Johansson K; Lindberg K; Dahlbäck B
    Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
    Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR
    Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
    Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.